NewAmsterdam Pharma Company N.V. (NAMS)
Nasdaq: NAMS · Pharmaceutical Preparations · Narrden, NL · filing with the SEC since 2022
Filings
247 filings since 2017 beside 168 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026Due nextLarge accelerated filer
10-K
Annual report for the fiscal year ending Dec 31, 2026Large accelerated filers have 60 days after the fiscal year ends.
by Mar 1, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by May 10, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. The proxy statement was last filed May 6, 2026.
Filings a yearinsider forms included
537310111474
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 10 times in the last 36 months, the newest Aug 14, 2026.Warning not to rely on past financial statements (8-K item 4.02): 1 time in the last 36 months, the newest Oct 18, 2024.SEC letters: 11 in the last 36 months, the newest Mar 6, 2025.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Jun 3, 2026
8-K items 5.02, 5.07, 9.01
Officer or director change; Shareholder vote · Current report
Jun 2, 2026
Jan 9, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
Nov 5, 2025
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
40 of 247 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.